NeonMind Biosciences Inc

At NeonMind Biosciences, we believe in “mind over matter”. We plan to help people change their lives by changing their minds, through treatment with psychedelics.

Recent News

  • NeonMind Developing Music Playlist for Psychedelic Therapy Sessions

    Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) -  NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (OTC PINK: NMDBF) ("NeonMind"), is pleased to announce the commencement of a three phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic sessions. Previous research has established that music for a therapeutic psychedelic session can significantly impact the experience. Figure 1: NeonMi

    2021-04-06 6:00 AM ET
  • NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference

    Vancouver, British Columbia--(Newsfile Corp. - March 30, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce that Robert Tessarolo, President & Chief Executive Officer, will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference that will be held virtually from May 4-6. He will be speaking on the use of psychedelics in treating obesity and eating disorders.

    2021-03-30 6:00 AM ET
  • NeonMind CEO Provides Update on the Progress of its Psilocybin Drug Development Research Plan and Team

    Vancouver, British Columbia--(Newsfile Corp. - March 23, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FSE: 6UF) ("NeonMind"), provides an update from CEO Rob Tessarolo on its research and development activities, as well as its plan to further develop two of its synthetic psilocybin-based drug candidates for the treatment of obesity, compulsive eating disorder and as an aid to weight loss and its maintenance.NeonMi

    2021-03-23 2:00 AM ET
  • NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity

    Vancouver, British Columbia--(Newsfile Corp. - March 11, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FSE: 6UF) ("NeonMind") is pleased to announce that on March 10, 2021 NeonMind engaged Certara®, the global leader in model-informed drug development to provide strategic integrated drug development support for the investigation of NeonMind's psilocybin based drug candidates for the treatment of obesity.Figure

    2021-03-11 7:00 AM ET
  • NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for Obesity

    Vancouver, British Columbia--(Newsfile Corp. - March 9, 2021) -  NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FSE: 6UF) ("NeonMind") is pleased to announce that on March 4, 2020 NeonMind engaged Philippe Martin as a drug development consultant.Figure 1: NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for ObesityTo view an enhanced version of Figure

    2021-03-09 3:00 AM ET
  • NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data

    Vancouver, British Columbia--(Newsfile Corp. - March 2, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMDBF) (FSE: 6UF) ("NeonMind") is pleased to announce that it has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind's preclinical trial. NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data

    2021-03-02 7:00 AM ET
  • NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial

    Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FFE: 6UF) ("NeonMind"), announces that it has purchased an initial order of GMP grade psilocybin from Psygen Labs Inc. ("Psygen") for its planned phase 2 human clinical trial expected to begin in Canada later this year. NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial

    2021-02-24 4:01 AM ET
  • NeonMind Submits Applications to Health Canada for Product Formulas to Support Cognitive and Immune Function and to Fight Stress

    Vancouver, British Columbia--(Newsfile Corp. - February 10, 2021) -  NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), announces that through its consumer products division, it submitted on February 2, 2021 four applications to Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD), to obtain product licenses for its products with 100% plant-based extracts, and make their related health claims.

    2021-02-10 7:00 AM ET